T he health care disparities in the United States described decades ago by Gornick et al 1 persist and are linked to social determinants of health and equality, [2] [3] [4] among them poverty, poor education, differences in medical insurance coverage, geographic location, legal or social status, race or gender, patient and community attitudes, and perceptions. 5 A systematic review by Haider et al 6 suggested that insurance status, median income, race, BACKGROUND: US health care disparities persist despite repeated countermeasures. Research identified race, ethnicity, gender, and socioeconomic status as factors, mediated through individual provider and/or systemic biases; little research exists in anesthesiology. We investigated antiemetic prophylaxis as a surrogate marker for anesthesia quality by individual providers because antiemetics are universally available, indicated contingent on patient characteristics (gender, age, etc), but independent of comorbidities and not yet impacted by regulatory or financial constraints. We hypothesized that socioeconomic indicators (measured as insurance status or median income in the patients' home zip code area) are associated with the utilization of antiemetic prophylaxis (as a marker of anesthesia quality). METHODS: We tested our hypothesis in several subsets of electronic anesthesia records from the National Anesthesia Clinical Outcomes Registry (NACOR), fitting frequentist and novel Bayesian multilevel logistic regression models. RESULTS: NACOR contained 12 million cases in 2013. Six institutions reported on antiemetic prophylaxis for 441,645 anesthesia cases. Only 173,133 cases included details on insurance information. Even fewer (n = 92,683) contained complete data on procedure codes and provider identifiers. Bivariate analysis, multivariable logistic regression, and our Bayesian hierarchical model all showed a large and statistically significant association between socioeconomic markers and antiemetic prophylaxis (ondansetron and dexamethasone). For Medicaid versus commercially insured patients, the odds ratio of receiving the antiemetic ondansetron is 0.85 in our Bayesian hierarchical mixed regression model, with a 95% Bayesian credible interval of 0.81-0.89 with similar inferences in classical (frequentist) regression models. CONCLUSIONS: Our analyses of NACOR anesthesia records raise concerns that patients with lower socioeconomic status may receive inferior anesthesia care provided by individual anesthesiologists, as indicated by less antiemetics administered. Effects persisted after we controlled for important patient characteristics and for procedure and provider influences. Findings were robust to sensitivity analyses. Our results challenge the notion that anesthesia providers do not contribute to health care disparities. (Anesth Analg 2018;126:588-99)
Antiemetic Prophylaxis as a Marker of Health Care Disparities in the National Anesthesia Clinical Outcomes Registry
Michael H. Andreae, MD,* Jonah S. Gabry, MA, † Ben Goodrich, PhD, ‡ Robert S. White, MD, § and Charles Hall, PhD∥ raises alarm about the persistent racial and ethnic disparities in the treatment of pain, clearly a domain of anesthesiologists. We described language as an access barrier to chronic pain services. [10] [11] [12] Jimenez et al 13 found disparities in pain treatment in children. Unfortunately, apart from labor analgesia [14] [15] [16] [17] and pain medicine, [18] [19] [20] [21] the literature on anesthesia-related health disparities seems sparse. 5 , 22 Spencer et al 22 expressed concern that "differences in payment between public and private payers may result in inferior care" and more patient safety events.
Objective
We sought to explore if health care disparities are also prevalent in anesthesiology and examined the contribution of individual providers. Our objective is to investigate if antiemetic prophylaxis as a marker of quality anesthesia care was independently associated with socioeconomic status, indicating health care disparities attributable to anesthesiologists. Previous research showed remarkable variability between providers in antiemetic utilization, possibly due to gaps in knowledge, or provider perceptions of importance of postoperative nausea and vomiting (PONV) as an outcome for the patient at hand, leading to underutilization of proven therapies. 24 Several arguments support antiemetic prophylaxis as a suitable marker of anesthesia quality.
• Antiemetic prophylaxis is relatively independent of patient comorbidities.
• It is indicated contingent on specific measurable risk factors for PONV.
• A standard of care with explicit guidelines is widely accepted. 25, 26 • Antiemetic administration is the sole responsibility of anesthesia providers.
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• Regulatory or insurance constraints have not yet impacted treatment choices.
• Antiemetic prophylaxis clearly improves outcomes. 25 • PONV prevention is a patient-centered outcome. 27 
Approach
We encountered 2 contradicting dilemmas, inherent in any electronic medical records-based health disparities research ( Figure 1 ):
1. Investigating the association between antiemetics and socioeconomic status (SES), we may want to control for confounding by including known risk factors for PONV, eg, age or gender. Including more potential confounders may reduce spurious associations.
2. Electronic anesthesia records uploaded to National Anesthesia Clinical Outcomes Registry (NACOR) are missing data, partly because participating institutions differ in the data they upload. In a regression analysis, we cannot include any case missing confounder variables. Therefore, attempting to control for more confounders makes the data set smaller and less representative.
On the one hand, a crude analysis may fail to adjust for potential confounders leading to biased results. On the other hand, concerns about generalizability make limiting our regression to only complete cases (with all data on all confounders) problematic; complete cases may not be representative of overall anesthesia practice, introducing selection bias. Complicating the analysis further, anesthesia and health care delivery are clustered in hospitals/services/providers 28 ; this hierarchical structure needs to be considered in statistical modeling for correct inferences. 29 Any statistical modeling approach is open to critique for being too crude or overcomplicated. Worse, model misspecification, for example, controlling for too many confounders, can lead to incorrect inferences. To compellingly attribute the disparities to the individual anesthesia provider, we wanted to convince the reader of the robustness of the association between antiemetic utilization and SES. Hence, we investigated the association between antiemetics and SES in a spectrum of models and data sets. We considered crude models (including all data) as well as several increasingly sophisticated regression analyses applied to progressively smaller "complete cases" data sets. This is outlined in the flow diagram ( Figure 2 ). We effectively conducted sensitivity analyses to cover the range between no adjustment versus potential over adjustment, complete data versus complete cases, and frequentist versus Bayesian statistical approaches, across different subsets of NACOR data ( Figure 1 ). Figure 1 . Missing data in electronic anesthesia records lead to a trade-off between selection bias and confounding bias in research using large databases like NACOR. Inferences based on the analysis of the complete data set or the larger enriched data sets will more likely be generalizable, but lack of control for confounders (age and gender) may lead to bias. As we control for confounding with increasingly complex models, adding more variables, the data set becomes smaller due to missing data: We can only include records with complete data in the analysis. Any increase in validity with advanced modeling may come at the expense of generalizability due to selection bias: The few institutions uploading all variables of interest may not represent typical anesthesia practice. NACOR indicates National Anesthesia Clinical Outcomes Registry; PUF, Public User File.
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Antiemetics as a Marker of Health Care Disparities
Hypothesis
Our hypothesis is that socioeconomic patient characteristics are consistently associated with antiemetic prophylaxis as a marker of anesthesia quality in NACOR.
METHODS
We prespecified our hypothesis and our analysis methods (Supplemental Digital Content 1, Appendix 1, http://links. lww.com/AA/C105). We obtained the NACOR Public User File, from Quarter 4 of 2013, enriched with additional information on antiemetic usage and insurance status by the Anesthesia Quality Institute (AQI). The Albert Einstein College of Medicine Institutional Review Board determined that our study does not meet the definition of human subject research as defined by 45 CFR 46.102(f), as AQI removed all identifiers.
NACOR receives information on anesthesia cases from participating institutions and anesthesia providers. 30 The data had been uploaded by participating provider institutions. Participating providers upload a minimum data set to NACOR, containing mostly demographics. Only few providers additionally uploaded the complete electronic anesthesia record including intraoperative physiologic data and administered medications.
Our unit of analysis is the anesthesia case. Without patient identifiers, repeated anesthetics provided to the same individual could not be identified and therefore were analyzed independently. In Quarter 4 of 2013, NACOR contained about 1 million complete electronic anesthesia records. Our AQI-created customized data subset contained 441,645 cases (full subset), where intraoperative antiemetic utilization was electronically accessible; antiemetics were utilized in 234,453 cases.
Our customized data set specified administration of the antiemetics dexamethasone, droperidol, ondansetron, and/ or phenergan; patient demographics and American Society of Anesthesiologists Physical Status Classification; provider identifier; institution and location; procedure codes; and some other case characteristics. Hence, we were limited to the most widely used antiemetics ondansetron and dexamethasone, with the strongest supporting evidence base. We omitted droperidol with its boxed warning by the Food and Drug Administration. Unfortunately, the timing of antiemetic administration intraoperatively versus postoperatively was not specified. The NACOR set contained the median income based on patient's zip rounded to $1000, generic and detailed insurance information, but with missing data for many cases as detailed in Supplemental Digital Content 2, Table 1 , http://links.lww.com/AA/C106.
We described the population characteristic of the NACOR data sets forming the bases of our analysis, ie, anesthesia records with complete information on the administration of antiemetic prophylaxis and/or insurance information, procedure code, median income, etc. We explored the bivariate associations between antiemetic utilization and independent variables describing patients, procedures, and providers. We defined our dichotomous outcome as the administration of ondansetron and/or dexamethasone. Patient characteristics included medical insurance status (as our primary predictor/independent variable of interest), patient age, gender, and American Society of Anesthesiologists Physical Status Classification. Neither race nor ethnicity was recorded in NACOR. We reported procedure types and indications (billing code, modifiers, and indication international classification of disease code). Provider characteristics included information on the anesthetist (nurse anesthetist versus resident versus attending alone) and institutional data (geographic location, academic versus private versus government institution).
Statistical Analysis
We explained in the introduction why we preferred a priori to utilize several concurrent statistical approaches to analyze the data. We wanted to demonstrate the consistency of the statistical association regardless of modeling choices. A complete case analysis of a limited subset with complete data on arbitrarily selected independent variables would have raised concerns about selection bias (Figure 1 ). Also, we wanted to preempt critique of our model specification. We employed 1. bivariate analysis, 2. stratified analysis, 3. logistic regression models, and 4. mixed effects hierarchical Bayesian models.
We compared the different approaches provided above in sensitivity and subgroup analyses. We investigated if any potential association between SES and antiemetic prophylaxis depended on the mode of analysis and/or on the inclusion or exclusion of potential confounders. We present several of our analyses with the code used to generate them (Supplemental Digital Content 3, Appendix 2, http://links. lww.com/AA/C107). We rarely if ever reported P values. The strength of the statistical association (also known as P value) is less relevant for our inferences, likely inflated, and possibly spurious, given the sheer size of our data. 31 AQI had removed all patient identifiers, which made it impossible to fit models to account for possible within-subject correlation. However, within-subject correlation tends to affect the confidence interval (CI), but less the point estimate of effect. Therefore, correction for within-subject correlation would likely not have affected our inferences, given the very low P values observed in our Big Data analysis.
Bivariate and Stratified Analysis. We used classical (frequentist) parametric tests where the assumptions of normality did not seem violated. We used nonparametric tests where graphical or statistical tests suggested possible violations of the underlying assumptions. In the table of characteristic of patients, we reported frequency (%), mean (±standard deviation), or the median (with the interquartile range) as appropriate for the distribution of values observed for each parameter and indicated the statistical test used.
We calculated odds ratios (ORs) for the association between insurance status and antiemetic administration and with the data stratified by gender, age, and other demographics and case characteristics. We described the population characteristics in Supplemental Digital Content 4, Table 2 , http://links.lww.com/AA/C108.
Classical Frequentist Logistic Regression. We fit classical (frequentist) logistic regression models in the subsets of anesthesia cases in the NACOR with information on intraoperative antiemetic administration and medical insurance status. We described the population characteristics in Supplemental Digital Content 5, Table 3 , http://links.lww. com/AA/C109. We investigated the association of medical insurance with the administration of antiemetic medication as the primary outcome variable, controlling for potential confounders including patient characteristics, provider characteristics, and procedure type and indication. Insurance status can be seen as a categorical variable; possible values are (unordered) private commercial insurance, Medicare, Medicaid, and Self-pay and including no medical insurance reported. We collapsed them to 4 unordered categories: Self, Medicaid, Medicare, and Commercial. Our outcome is dichotomous, antiemetic prophylaxis administered or not. Our unit of analysis is the anesthesia case, not the patient. We focused our analysis on the most frequent procedures performed. We considered findings statistically significant if the P value was less than the type I error rate of .01.
A priori, we included gender and age as likely confounders, because they are known risk factors for PONV. Given the increased power of our analysis in such a big data set, the exploration of confounding and interaction should be limited and preordained a priori to prevent the detection of spurious associations. For the initial model, we chose those independent variables that showed a statistically significant association in the bivariate analysis. We used a stepwise backward elimination model selection technique. We eliminated independent variables from the model based on the likelihood ratio test with a cutoff at 0.05. For each elimination, we confirmed that the given variable was not a confounder for the present model. A change in the β coefficient of larger than 20% was used as our cutoff to determine if a variable was considered a confounder. This is admittedly an arbitrary cutoff, 32 deliberately conservative to prevent overfitting. 33 We determined the correct functional form and explored potential violations of the assumptions of linearity. We graphically assessed for potential violations of the assumption of linearity by running locally weighted regression and examined the graph for all independent variables in our final model. We tested for the correct functional form, fitting fractional polynomials as a part of our final logistic regression model. We examined if the addition of a polynomial improves the model significantly. We explored the potential interaction between the independent variables age and gender in a logistic regression model; a cutoff for our likelihood ratios test was at a type I error rate level of 0.05. We did not consider the goodness of fit with the HosmerLemeshow goodness-of-fit test, because it will erroneously detect small departures from the proposed model as significant in large data sets. 34, 35 Instead, we calculated the concordance statistic. Bayesian Hierarchical Model. We built hierarchical Bayesian models for the subset with data on medical insurance (short: insurance) and median income in patient home zip code (short: income). We described the population characteristics in Supplemental Digital Content 6, Table 4 , http://links. lww.com/AA/C110. We used Bayesian approaches after classical mixed effects models failed to converge due to the large size of the population studied. Bayesian and classical inference will give similar inferences, but, for large data sets, frequentist models often fail to converge. We overcame this hindrance with Bayesian estimation of probability distributions using Hamiltonian-Markov chain Monte Carlo simulation, a faster and novel, more robust algorithm. 37 We studied the administration of only ondansetron or of ondansetron and dexamethasone as primary outcomes. We included either insurance or income (divided in quantiles) as categorical independent variables in our models. We controlled for patient characteristics such as gender and age (Table 2 ) and other patient, procedure, or anesthetic-related confounders (Tables 3 and 4) . In some models, we included mixed (random) effects to control for the potential confounding influence of procedure type or provider behavior, by allowing each procedure and each provider to have an individual intercept. We present more formal details on the Bayesian modeling in Supplemental Digital Content 7, Appendix 3, http://links.lww.com/AA/ C111.
We relied on Gelman Rubin convergence diagnostic as a convergence diagnostic, after exploring the Monte Carlo Markov chain output graphically. 37 , 38 Gelman Rubin convergence diagnostic, developed by Rubin and Gelman, is comparing between and within variances of multiple chains in Marcov chain Monte Carlo simulations, to assess convergence of multiple chains run in parallel. Individual chains are initialized with different starting values. After discarding the burn in, convergence is assumed, when the output from all chains is indistinguishable. In simple terms, chains "forgot" their starting values, when individual chains have become independent of initialization. Values <1.1 indicate convergence. 39 Bayesian Prior Distributions. In Bayesian parlance, 37 the use of informative Bayesian prior distributions refers to incorporating existing knowledge about parameters into the model. For example, the choice of prior could force the estimated treatment effect in a clinical trial to tend to fall within reasonable bounds. Such a prior would express our disbelief in a miracle drug. 40 Informative Bayesian prior distributions are possibly more relevant for Bayesian meta-analysis. 41, 42 In contrast, uninformative Bayesian prior distributions relax any such constraints, leading Bayesian and classical statistical approaches to converge to similar inferences. 37 We used the default uninformative Bayesian prior distributions, as described in the software package. 43 These uninformative priors for the main effect of insurance status on antiemetic prophylaxis are spelled out both formally and as function call to rstanarm in Supplemental Digital Content 7, Appendix 3, http://links.lww.com/AA/C111.
We performed a sensitivity analysis investigating prior distributions and our model specifications. Representative examples of various models, with fixed and/or random intercepts and slopes, are presented in Supplemental Digital Content 3, Appendix 2, http://links.lww.com/AA/C107.
Contrasting Different Modeling Approaches and Sensitivity
Analyses. We contrasted the results of our 3 models (bivariate, logistic regression, and Bayesian analysis) to confirm the robustness of our findings regardless of the model choices or statistical approach chosen (Figure 1 ). We performed a sensitivity analysis of our model assumptions and choices with various data subsets. In particular, we fit the stratified and regression analyses to the multilevel subset. Detailed code and selected results are presented in Supplemental Digital Content 3, Appendix 2, http://links.lww.com/AA/ C107. However, the different model specifications (bivariate versus standard linear regression versus hierarchical/ mixed effects) and different fixed and random effects (procedure versus provider random effects) meant that models were not always nested. While equivalent for inferences, one should expect to see somewhat different estimates for the regression coefficients in the different models. 
Software Used
We used the statistical software Stata (StataCorp, LLC, College Station, TX) for the logistic regression and bivariate analysis. 43 The public domain statistical software package R/Rstudio (RStudio, Vienna, Austria) and the probabilistic programming software STAN were used in conjunction with the R software packages rstan and rstanarm 43, 45, 46 (
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RESULTS
Description of the Data Set
The flow diagram in Figure 2 details the NACOR subset used for each of our statistical analyses. Our AQI-created customized data set contained 441,645 cases (full subset) where intraoperative utilization of the antiemetic dexamethasone or ondansetron was electronically accessible. Dexamethasone and/or ondansetron were utilized in 233,498 cases. Dexamethasone only was administered in 86,280 and ondansetron only in 223,472 cases. Both antiemetics were used together in 76,254 cases. The reporting institutions were mostly Northeastern university hospitals or medium to large Southern community hospitals. Our data set contained no cases from the Midwest or the West of the United States. Anesthesia was provided between January 1, 2010, and December 31, 2013.
Unfortunately, the Public User File (4th quarter 2013) only contained 441,645 cases with detailed information on medications administered during anesthesia. Six unique institutions reported antiemetic utilization, complete demographics, and insurance status for 173,133 anesthesia cases, of the 12 million cases in NACOR. The data set shrank further, when we limited this set further to cases with information on additional independent variables for our regression analysis (n = 115,751) and our Bayesian hierarchical model (n = 92,683).
Population Characteristics and Bivariate Analysis of Demographic Characteristics
The demographics of the population in the NACOR database with information on antiemetic administration are described in Table 1 . Forty-three percent of anesthetics were administered to male patients. Patients' age ranged from newborn to 90 years of age with a median of 52 (interquartile range, 35-67 years). Most patients were classified as ASA physical status II and III (35% and 30%, respectively) with few cases in ASA physical status V. Sixty-two percent were outpatients among the 64% of cases where this information The stratified analysis of ondansetron utilization is exemplified by gender and anesthesia type and shows the odds of antiemetic administration by insurance status for each stratum. The OR compares the odds to the reference population with commercial insurance (with the upper and lower 95% confidence interval in the following column) and favors commercial insurance over Medicaid and Medicare in all strata in this NACOR data set (n = 173,133) with complete information on insurance and antiemetic utilization (P < .01), reported by 4 institutions. Abbreviations: MAC, monitored anesthesia care; NA, not applicable; NACOR, National Anesthesia Clinical Outcomes Registry; OR, odds ratio.
was available. Insurance status was reported as Medicaid for 25,865 cases (5.9%), Medicare for 51,441 cases (12%), and commercial insurance for the remaining 97,443 cases (22%), with 1585 cases (0.36%) self-insured, but insurance status was not available in 265,311 cases. "Self-pay" may reflect charity care in some and high SES of the patient in other settings. Therefore, "self-pay" may be a poor indicator of SES. Insurance was reported as "self-pay" in only a small fraction of cases (<0.5% of cases in Table 1 ). "Self-pay" was the only predictor with inconsistent results, likely due to the small numbers. At least 1 antiemetic (either ondansetron or dexamethasone) was administered in 53% of the NACOR full subset case. We stratified the NACOR data set with complete information on insurance status and antiemetic administration into levels by potential confounders as a crude but robust approach to correct for potential confounding. We calculated the ORs for receiving an antiemetic. We explored the preponderance for antiemetic prophylaxis using ondansetron and/or dexamethasone. In Table 2 , we present a stratified analysis by gender and anesthetic choice showing ondansetron utilization contingent on patient insurance status. For example, patients on Medicaid are less likely to receive antiemetic prophylaxis than those with commercial insurance, regardless of gender. The OR was similar for women (0.59; 95% CI, 0.57-0.61) as for men (0.55; 95% CI, 0.52-0.57). The results were consistent regardless of antiemetic (data not shown).
Stratification sometimes changed the ORs, for example, contingent on anesthesia type, as we would expect for confounders. In Table 2 , comparing Medicaid versus commercial insurance, the OR ranged from 0.53 (95% CI, 0.51-0.54) under general anesthesia to 0.82 (95% CI, 0.76-0.87) under neuraxial anesthesia. However, regardless of anesthesia type, Medicaid status was associated with significantly reduced odds of receiving antiemetic prophylaxis. The strong and consistent association between insurance status and antiemetic prophylaxis held also when we fit stratified analyses to the multilevel subset (data not shown).
Ondansetron was more often used in longer cases, and in outpatients, and less during emergency surgery, and more frequently if the patient lived in a zip code with higher mean income and smaller population size. Results suggested that patients who received ondansetron were, on average, younger. Ondansetron was more frequently given to women (P < .001).
Regression Analysis
Classical Frequentist Logistic Regression Model. Being on Medicaid or Medicare, compared to having commercial insurance, drastically reduces the odds of receiving ondansetron during anesthesia. For the average patient on Medicare (or similarly, Medicaid), the odds of receiving ondansetron for antiemetic prophylaxis are 0.64, with a 95% CI of 0.62-0.66 compared to a patient with commercial insurance with otherwise similar characteristics. This reflects the association after controlling for age and gender, case duration, median income, and population in the patient's home zip code. We present the results of our final logistic regression model in Table 3 , modeling ondansetron use only by patient insurance status as socioeconomic indicator and controlling for age and gender. The concordance statistic for the classical logistic regression was calculated as 0.73, which indicates good model fit. 35 We found similar results when we fit the regression analyses to the multilevel subset (data not shown).
Hierarchical Bayesian Generalized Linear Models. We also fitted more complex hierarchical Bayesian mixed effects models to control for procedure and provider influences in the propensity to administer antiemetics. In all contrasts, we consistently found strongly and significantly reduced ORs for receiving antiemetic prophylaxis (using ondansetron alone or either ondansetron and/or dexamethasone as outcomes) for patients with lower SES, after we fitted several hierarchical mixed effects Bayesian models (including random intercepts for anesthesia provider, institution, or procedure). In Table 4 , we present the contrast of the reference category commercial insurance versus Medicaid (and versus Medicare insurance). In Supplemental Digital Content 8, Table 5 , http://links. lww.com/AA/C112, we present the association of median income in the patients' home zip code with antiemetic prophylaxis. We present the detailed results of several modes in Supplemental Digital Content 3, Appendix 2, http://links. lww.com/AA/C107, for transparency. The convergence of our Bayesian models was confirmed by looking at trace plots and the Gelman Rubin statistics, 48 shown for selected parameters of our Bayesian models.
We show the ORs (with 95% Bayesian credible intervals) of 2 representative Bayesian hierarchical mixed effects model in Table 4 and in Supplemental Digital Content 8, Table 5 , http://links.lww.com/AA/C112. They reflect the effect of insurance and median income in the patients' home zip code as independent variables of interest. The association between socioeconomic indicator and antiemetic prophylaxis was consistent regardless of what variable we used as a measure of SES.
We modeled ondansetron administration in the NACOR subset of anesthesia cases with complete data on insurance status, antiemetic administration, and provider and procedure code (n = 92,683). Results are reported in Table 4 . Compared to commercial insurance, Medicaid and Medicare patients were less likely to receive antiemetic prophylaxis with ondansetron (OR, 0.85, with a 95% Bayesian credible interval, 0.81-0.89), after controlling for age, gender, ASA physical status, anesthesia type, and type of practice as fixed effects, allowing providers and procedures a random intercept. The concordance statistic for this Bayesian hierarchical model was calculated as 0.91, which indicated an excellent model fit. 35 This concordance statistic of the Bayesian hierarchical model was larger than the concordance statistic for the classical linear regression model, which should not surprise given that we fitted individual intercepts for the individual anesthesia providers and procedure.
Modeling median income as quantiles, patients were more likely to receive antiemetic prophylaxis with any antiemetic if they lived in neighborhoods (zip codes) with high median income (OR, 1.16, with Bayesian credible 95% interval, 1.09-1.25) or middle median income (OR, 1.10, with Bayesian credible 95% interval, 1.05-1.17) compared to neighborhoods with very low median income. Detailed results are presented in Supplemental Digital Content 8, Table 5 , http://links.lww.com/AA/C112.
As we would expect given the known risks for PONV, women and the younger (reference age group, 19-49 years) patients were more likely to receive prophylaxis (as indicated by older patients' OR <1). More prophylaxis was administered in cases using general anesthesia. Increasing ASA physical status was associated with lower odds of prophylaxis. Differences between institutions were large, suggesting that health care disparities may be endemic, ie, locally more or less pronounced.
Sensitivity Analysis
The strong and statistically significant association between indicators of patients' SES (insurance status or median income in the patients' home zip code) and the odds of receiving antiemetic prophylaxis remained unchanged after stratification to control for the patient characteristics such as gender and age (Table 2) in our logistic regressions (Tables 3  and 4 ). Our inferences were invariant to the statistical approach (Bayesian versus classical frequentist analysis) used and bore out in the full subset and any subset used for multivariable logistic regression. In Supplemental Digital Content 3, Appendix 2, http://links.lww.com/AA/C107, we presented several additional analyses to corroborate the consistency of our findings.
DISCUSSION
Summary of the Findings
In our enriched NACOR data set, we found a clinically meaningful and statistically strong association between SES (insurance status or median income in home zip code) and the utilization of antiemetic medication (ondansetron and/ or dexamethasone), regardless of the modeling approach used. The magnitude of the difference is large: 40% of patients on Medicaid receiving antiemetics versus 60% of patients with commercial insurance would correspond to a number needed to treat of 5. In our most refined Bayesian hierarchical mixed regression model, the OR of receiving the antiemetic ondansetron is 0.85 for Medicaid versus commercially insured patients, with a 95% Bayesian credible interval of 0.81-0.89. Inferences were robust to sensitivity analyses.
We believe that SES or payer should not influence PONV prophylaxis. 50 Given that antiemetic administration is the sole domain of the individual anesthesia providers, our results point to possible, unappreciated, and worrisome health care disparities in anesthesia. 51 The size of the NACOR data set we studied likely makes this the largest study of health care disparities in anesthesia undertaken to date. Controlling for likely confounders decreases the chance that the association is spurious. Demonstrating health care disparities for which only anesthesiologists are accountable, in such a large data set, is novel. Disparity in antiemetic utilization (as a marker of anesthesia quality and exclusively in the domain of the anesthesiologist) will likely make a greater impression on the anesthesia community than differences in which anesthesiologists are only marginally involved (eg, procedure time 5 ) or where anesthesiologists are not the sole decision maker. 14 
Generalizability
The comprehensive records uploaded to NACOR mostly by academic institutions in the North East are likely not random or representative samples of anesthesia practice 52 Differences in demographic characteristics between NACOR subsets neither prove nor disprove generalizability. More importantly, the rich heterogeneity of anesthesia practice in the United States (apparent in the variability of the case mix between institutions and the diversity of its providers) defeats any single simplified modeling approach; a description of the typical anesthetic is as useful as the description of the typical American (voter, consumer, etc). [53] [54] [55] The observed disparities seem pervasive, even though we concede (and hope) that they may not be ubiquitous. Our findings compel because they are consistent across different data sets and are indifferent to modeling approaches. 56 
Critique of the Modeling Approach
Which of our models is the best? Box 57 reminded us that "all models are wrong, some are useful" and argued for robustness (which, however, is no guarantee for correct inferences). We discuss below confounding, missing data, model misspecification, and overfitting as potential limitations of our bivariate, multivariable, Bayesian model specifications and illustrate the tradeoff in Figure 1 . All our models provided evidence against our null hypothesis of no anesthesia-related health care disparities. 58 Our final random effects modeling by individual provider and procedure, in conjunction with the redundancy and multiplicity of our sensitivity analyses of different subsets together, might serve as a model to address this challenging complexity of Big Data health disparities research. 59 Confounding, Missing Data, and Model Misspecification. Age, gender, history of PONV, and smoking are the 4 most important commonly accepted risk factors for PONV. It is a limitation of our work that we controlled only for the first 2. In our anecdotal experience, however, only gender and age are routinely elicited preoperatively by anesthesia providers and used for decision making regarding antiemetic prophylaxis. 25 We attempted to partially (but admittedly incompletely) control for postoperative opioid administration with 1. fixed effects for anesthesia type (regional versus general anesthesia) and 2. random effects for (a) procedure (related need for opioids) and (b) provider (individuals' propensity to administer opioids versus nonsteroidal anti-inflammatory drugs).
Stratified analysis only controls for the specific variable by which the stratification is done, and substratification quickly becomes overwhelming. Logistic regression does not control well for confounding when the probability of effect is around 50%. Hierarchical models lead to shrinkage, which makes for a better fit of the model to the data, but this may lead, among other issues, to overfitting.
However, our results were invariant to our statistical approach. Bivariate analysis, stratification, and hierarchical Bayesian or classical frequentist logistic regression all led to the same inferences. We controlled for many patient characteristics including ASA physical status, age, and gender (Tables 3 and 4) . We controlled for the choice of anesthetic given. We considered surgical procedure and provider as confounding factors by allowing individual random intercepts, implemented in a Bayesian hierarchical model. Likewise, while there was considerable missing data as detailed in the flow diagram in Figure 2 , the health care disparities were apparent across all data subsets analyzed.
In our enriched NACOR data set, reporting of antiemetic utilization did not differentiate intraoperative (when antiemetics would have been administered for prophylaxis) versus postoperative use (when antiemetics might have been given as treatment for active nausea and vomiting). While consistent undertreatment of patients of lower SES would be equally concerning as inferior prophylaxis, treatment in the postanesthesia period is no longer under the sole domain of the anesthesia providers. We concede that this limits our inferences. Not all providers and institutions use electronic anesthesia records. Some upload only selected data to NACOR, eg, for regulatory or privacy reasons. All the foregoing may limit the generalizability of our findings. Hence, our analysis should be repeated in other larger electronic anesthesia databases. We should investigate the effect of additional markers of SES (eg, scholastic attainment, social networks). Also, providers may have forgotten to record the administration of antiemetic medication, but still have administered the prophylaxis. Such misclassification could lead to an overestimation or underestimation of anesthesia health care disparities.
We did not control for smoking, an important PONV risk factor. Smoking arguably is associated with SES. Beyond lamenting this limitation, we conceptualize this as a potential mechanism to explain the observed disparity. 60 Smoking status is rarely accessible in the preoperative anesthesia evaluation or transmitted in handovers. We hypothesize that when providers decide on antiemetic prophylaxis, they infer smoking status from patients' aspect and appearance, which may lead to bias. Looking at the author of this article, anesthesia providers may think "this old bearded sailor does not need prophylaxis," when, based on history and smoking status, the opposite is true.
Those who do not accept antiemetic prophylaxis as a valid indicator of anesthesia quality will have to concede that disparities in antiemetic prophylaxis due to insurance or SES are worrisome. On the other hand, while insurance status and median income in patients' home zip code are closely linked to race and SES, they may not be the best predictors of health care disparities. We furthermore concede that our cross-sectional analysis neither discerns causal pathways nor proves causation. We concede that we did not investigate other accepted approaches to PONV prophylaxis, for example, other antiemetic medications or nonpharmacological interventions including regional anesthesia, total intravenous anesthesia, and avoidance of nitrous oxide, not least because this information was not provided in our enhanced NACOR data set. Demonstrating the disparity for any antiemetic intervention should be concerning enough, although it would have been even more compelling to make the point for every single one. We focused instead on the simple choice of the anesthesia provider to administer a cheap, ubiquitously available, proven effective prophylactic agent, or not. We hope that other investigators will join us in a more comprehensive analysis of how practice patterns are influenced by SES.
Difference, Disparity, and Bias
In the process of quality improvement, we typically go through the 4 stages described succinctly by Berwick We hope to convince anesthesiologists with the presented strong, robust, and consistent association between insurance status and antiemetic prophylaxis with ondansetron and/or dexamethasone that the findings are solid (stage I). Disparity in anesthesia quality is a problem, even if it concerned not anesthesia quality in general, but only antiemetic prophylaxis (stage II). We think that there is a clear argument that the described association describes a health care disparity for which anesthesia providers are accountable (stage III). In the framework for interpreting socioeconomic and racial differences in health care, we demonstrated difference, disparity, and bias. 61 Anesthesiologists have a tradition as the leaders in perioperative quality improvement addressing individual performance as well as systems to improve care for all patients. 18 The next step would be to investigate what interventions (eg, electronically triggered reminders) might improve anesthesia quality regardless of patient characteristics.
CONCLUSIONS
Our analyses of the association between insurance status (as a marker of patient SES) and antiemetic administration (as a marker of anesthesia quality provided by the individual anesthesiologist) in the NACOR database admittedly fall short of proving the existence of bias among anesthesia providers, but still provide substantial evidence against our null hypothesis of no anesthesia-related health care disparities. 58 Further observational studies and possibly randomized trials 63 may be needed to convince the anesthesia community that, where there is smoke, there is fire. 63 Our novel modeling approach may be a first step toward addressing the rich multilevel heterogeneity inherent in electronic (anesthesia) records and characteristic of contemporary anesthesia practice in the United States. 53 ,65 E
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